102
Views
2
CrossRef citations to date
0
Altmetric
Commentary

Chelation of manganese by combining deferasirox, deferiprone and desferrioxamine in male rats as biological model

, &
Pages 151-156 | Received 23 Apr 2015, Accepted 17 Jul 2015, Published online: 18 Aug 2015

References

  • Aschner M, Erikson KM, Dorman DC. (2005). Manganese dosimetry: species differences and implications for neurotoxicity. Crit Rev Toxicol 35:1–32
  • Bowler RM, Gysens S, Diamond E, et al. (2006). Manganese exposure: neuropsychological and neurological symptoms and effects in welders. Neurotoxicology 27:315–26
  • Crossgrove J, Zheng W. (2004). Manganese toxicity upon overexposure. NMR Biomed 17:544–53
  • Dahooe Balooch F, Fatemi SJ, Iranmanesh M. (2013). Combined chelation of lead (II) by deferasirox and deferiprone in rats as biological model. Biometals 27:89–95
  • Domínguez Vera JM. (2004). Iron (III) complexation of Desferrioxamine B encapsulated in apoferritin. J Inorg Biochem 98:469–72
  • Erikson KM, Syversen T, Aschner JL, Aschner M. (2005). Interactions between excessive manganese exposures and dietary iron-deficiency in neurodegeneration. Environ Toxicol Pharmacol 19:415–21
  • Fatemi SJ, Amiri A, Bazargan MH, et al. (2007). Clinical evaluation of desferrioxamine (DFO) for removal of thallium ions in rat. Int J Artif Organs 30:902–5
  • Fatemi SJ, Tubafard S, Nadi B. (2009). Evaluation of the effect of cadmium on rat organs and investigation of diethyl carbamate as an oral drug in treatment of cadmium toxicity. Med Chem Res 18:179–86
  • Fatemi SJ, Shokooh Saljooghi A, Dahooee Balooch F, et al. (2011). Chelation of cadmium by combining deferasirox and deferiprone in rats. Toxicol Ind Health 27:371–7
  • Fatemi SJ, Khajoee Nejad F, Zandevakili T, Dahoee Balooch F. (2014). Chelation of cobalt by combining deferasirox, deferiprone and desferrioxamine in rats. Toxin Rev 33:146–50
  • Fukuda S. (2005). Chelating agents used for plutonium and uranium removal in radiation emergency medicine. Curr Med Chem 12:2765–70
  • Gerber GB, Lĭıonard A, Hantson PH. (2002). Carcinogenicity, mutagenicity and teratogenicity of manganese compounds. Crit Rev Oncol Hematol 42:25–34
  • Heinz U, Hegetschweiler K, Acklin P, et al. (1999). 4-[3,5-Bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]-benzoic acid: a novel, efficient and selective iron (iii) complexing agent. Angew Chem Int Ed 38:2568–71
  • Huang P, Chen C, Wang H. (2011). Manganese effects in the liver following subacute or subchronic manganese chloride exposure in rats. Ecotoxicol Environ Safe 74:615–22
  • Kaur G, Srivastava UC, Dwivedi RS, Srivastava RC. (1984). Influence of polyaminocarboxylic acids on the removal of manganese-54 from the body organs of sham-operated and partially hepatectomized rats. Toxicol Lett 22:1–6
  • Lebda M, El-Neweshy M, El-Sayed Y. (2012). Neurohepatic toxicity of subacute manganese chloride exposure and potential chemoprotective effects of lycopene. Neuro Toxicol 33:98–104
  • Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. (1997). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23:3–25
  • Liu DY, Liu ZD, Hider RC. (2002). Oral iron chelators – development and application. Best Pract Res Clin Haematol 15:369–84
  • Michael SM, James LB, Nazzareno B. (2009). Hepatic uptake and biliary excretion of manganese in the little skate, Leucoraja erinacea. Comp Biochem Physiol C 149:566–71
  • Montes S, Riojas Rodriguez H, Sabido Pedraza E. (2008). Biomarkers of manganese exposure in a population living close to a mine and mineral processing plant in Mexico. Environ Res 106:89–95
  • Pearson GF, Greenway GM. (2005). Recent developments in manganese speciation. Trend Anal Chem 24:803–9
  • Quintanar L. (2008). Manganese neurotoxicity: a bioinorganic chemist’s perspective. Inorg Chim Acta 36:875–84
  • Rollin H, Mathee A, Levin J, et al. (2005). Blood manganese concentrations among first-grade schoolchildren in two South African cities. Environ Res 97:93–9
  • Scott LE, Orvig C. (2009). Medicinal inorganic chemistry approaches to passivation and removal of aberrant metal ions in disease. Chem Rev 109:4885–910
  • Shokooh Saljooghi A, Fatemi SJ. (2010). Clinical evaluation of deferasirox for removal of cadmium ions in rat. Biometals 23:707–12
  • Shokooh Saljooghi A, Fatemi SJ. (2011). Removal of thallium by deferasirox in rats as biological model. J Appl Toxicol 31:139–43
  • Singh S, Epemolu O, Dobbin PS. (1992). Urinary metabolic profile in human and rat of 1,2-dimethyl and 1,2-diethyl substituted 3-hydroxypyridin-4-ones. Drug Metab Dispos 20:256–61
  • Tubafard S, Fatemi SJ. (2008). Chelation of bismuth by combining desferrioxamine and deferiprone in rats. Toxicol Ind Health 24:235–40
  • Tubafard S, Fatemi SJ, Shokooh Saljooghi A, Torkzadeh M. (2010). Removal of vanadium by combining desferrioxamine and deferiprone chelatores in rats. Med Chem Res 19:854–63
  • Zhang F, Xu Z, Gao J, et al. (2008). In vitro effect of manganese chloride exposure on energy metabolism and oxidative damage of mitochondria isolated from rat brain. Environ Toxicol Pharmacol 26:232–6
  • Zheng W, Fu SX, Dydak U, Cowan DM. (2011). Biomarkers of manganese intoxication. Neurotoxicology 32:1–8

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.